BioNTech SE American Depositary Share (BNTX) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2025
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covi...
BioNTech SE American Depositary Share's revenue increased 5.6% year over year, from $2.89B to $3.05B.
Net income decreased 70.8% over the same period, from $-665.3M to $-1.14B.
Over the 4-year period from FY2021 to FY2025, revenue declined by 84% in total.
Total debt increased by 5.2% to $267.4M.
The debt-to-equity ratio stands at 0.01, indicating a conservative leverage profile.
BioNTech SE American Depositary Share maintains a negative net profit margin of -37.2%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $18.98B | $10.29B | $16.07B | $15.28B | N/A | $15.83B | $301.5M | $11.89B |
| FY2022 | $17.31B-8.8% | $9.43B | $14.32B | $12.64B | N/A | $23.28B | $212.2M | $20.06B |
| FY2023 | $3.92B-77.3% | $930.3M | $3.32B | $690.4M | N/A | $23.01B | $219.1M | $20.25B |
| FY2024 | $2.89B-26.3% | $-665.3M | $2.35B | $-1.31B | N/A | $22.53B | $254.2M | $19.41B |
| FY2025 | $3.05B+5.6% | $-1.14B | $2.41B | $-1.40B | N/A | $21.99B | $267.4M | $19.22B |
Balance Sheet Summary (Latest Period)
Total Assets
$21.99B
Total Liabilities
$2.76B
Total Equity
$19.22B
Cash & Equivalents
$14.88B
Total Debt
$267.4M
Current Assets
$16.15B
Current Liabilities
$2.14B
Retained Earnings
$17.96B